drugset / Trial / NCT02182622
LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to first determine the highest dose of LDE225 combined wtih Docetaxel and Prednisone that can be given that does not cause unacceptable side effects when given to patients with castrate resistant prostate cancer who failed previous docetaxel therapy.
Timeline
- Start
- 2014-07
- Primary completion
- 2015-12
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 60 mg/m2 | Intravenous |
| Subject | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Subject | Sonidegib | Small molecule | 200 mg | Oral |
| Subject | Sonidegib | Small molecule | 400 mg | Oral |
| Subject | Sonidegib | Small molecule | 800 mg | Oral |
| Background | Prednisone | Other / unclassified | 5 mg | Oral |